RARA CRAFT DATABASE for FDA Medical Devices
510(k)K213803

FDA DEVICE FACTS

FIBERGRAFT Aeridyan Matrix Bone Graft Substitute

Prosidyan, Inc.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEAugust 23, 2022PRODUCT CODEMQV

Indications for use

FIBERGRAFT® Aeridyan

™ Matrix - Bone Graft Substitute is indicated only for bony voids or gaps th a t are not intrinsic to the stability of the bony structure.

FIBERGRAFT® Aeridyan

™ Matrix is indicated to be gently packed into bony voids or gaps of the skeletal system (i.e., the postero

lateral spine , extremities and pelvis ). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced with bone during the healing process. FIBERGRAFT® Aeridyan

™ Matrix must be used with autogenous bone marrow aspirate and autograft in posterolateral spine

. FIBERGRAFT® Aeridyan™ Matrix must be hydrated with saline or blood for pelvis and extremity applications.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 22, 2026